Hogan Lovells advises Myriad Genetics on reorganization of international business operations and sale of EndoPredict business

Press releases | 05 August 2024

Led by partner Peter Huber, an international team of global law firm Hogan Lovells advised Myriad Genetics on the reorganization of its international business operations. As part of the reorganization, Myriad Genetics has sold its EndoPredict business to Eurobio Scientific, a leading French group in the field of in vitro diagnostic medicine and life sciences.

The reorganization aims to better align Myriad’s resources with domestic opportunities while continuing to serve key partnerships with biopharmaceutical companies and patients outside the United States.

Myriad Genetics is a leading company in genetic testing and precision medicine. The company develops and offers genetic tests that help assess the risk of developing disease or disease progression and support treatment decisions in medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.

Hogan Lovells team for Myriad Genetics

Germany

Peter Huber (Partner), Tobias Flasbarth (Counsel), Dr Patrick Waldecker, Dr Artem Vesdenetski, Shervin Mir Marashi (Associates) (Corporate/M&A);

Dr Anna-Katharina Friese-Okoro (Partner), Benedikt Dellen (Senior Associate), Dr Fabian Flüchter (Associate) (Intellectual Property);

Dr Ingmar Dörr (Partner, Tax);

Dr Tim Joppich (Partner), Dr Justus Frank (Counsel), Annika Weber (Senior Associate), Dr Jana Lind (Associate) (Employment);

Dr Christoph Wünschmann (Partner), Johanna Brock-Wenzek (Counsel) (Antitrust);

Netherlands

Alexander Fortuin (Partner), Matthijs Dols (Senior Associate), Vera Brouwer (Associate) (Tax);

Marieke Plaisier (Associate), Jamie Tang (Paralegal) (Corporate/M&A);

Belgium

Julius Jakob Gertz (Associate, Global Regulatory);